10 Big Names With Explosive Gains That Investors Can’t Ignore

Page 9 of 9

1. uniQure NV (NASDAQ:QURE)

uniQure soared by 291 percent week-on-week to climb to a new all-time high as investors cheered the stellar performance of its potential drug treatment for Huntington’s disease.

In Friday’s session, uniQure NV (NASDAQ:QURE) soared to its highest 52-week price of $55.11 before trimming gains to end the day just up by 3.15 percent at $54.31 apiece.

This followed an announcement on the same day that its potential treatment slowed progression of Huntington’s disease by 75 percent after 36 months.

Uniqure NV (NASDAQ:QURE) said the drug candidate, AMT-130, was well-tolerated and that no adverse effects have been observed since 2022.

The company said that the Food and Drug Administration (FDA) has granted AMT-130 Breakthrough Therapy and Regenerative Medicine Advanced Therapy (RMAT) designations.

“We are incredibly excited about these topline results and what they may represent for individuals and families affected by Huntington’s disease,” said Uniqure NV (NASDAQ:QURE) Chief Medical Officer Walid Abi-Saab.

“These findings reinforce our conviction that AMT-130 has the potential to fundamentally transform the treatment landscape for Huntington’s disease, while also providing important evidence supporting one-time, precision-delivered gene therapies for the treatment of neurological disorders,” he noted.

While we acknowledge the potential of QURE to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than QURE and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.

Page 9 of 9